Q-omics provides the consensus-scored TRPV5 profile across patient tissues and cancer cell-line models. TRPV5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, TRPV5 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, TRPV5 protein abundance shows 14,145 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KICH, KIRC, and PDAC as cancer lineages where TRPV5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRPV5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRPV5 survival associations across molecular data types. TRPV5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRPV5 RNA expression–survival associations across cancer types. High TRPV5 expression shows unfavorable associations in KICH, THCA, ACC, READ and LUSC, but favorable associations in BLCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for TRPV5 RNA expression.
This table summarizes TRPV5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TRPV5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRPV5 shows lower tumor expression in KIRC, KIRP, KICH and THCA and higher tumor expression in COAD and PRAD. The KIRC box plot shows higher TRPV5 RNA expression in normal versus tumor tissue (log2 FC = −1.743, t-test p < 0.001).
This table shows molecular features associated with TRPV5 in patient tissues and cancer cell lines. In patient samples, TRPV5 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRPV5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
